A Study to Evaluate the Effectiveness, Safety and Tolerability of PF-06823859 In Adults With Moderate-to-Severe Dermatomyositis

Overview

Información sobre este estudio

The purpose of this study is to evaluate the investigational drug PF-06823859 and a placebo administered to adult pPatients with moderate-to- severe Dermatomyositis.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (e.g., corticosteroids). 
  • Confirmation of DM by the investigator and two of the following:
    • Gottron's papules;
    • Gottron's sign;
    • Heliotrope eruption;
    • Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;
    • Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;
    • Positive DM serology. 
  • Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study. 
  • Willing to provide 6 biopsies during the course of the research study.

Exclusion Criteria: 

  • Investigator site staff or members of their family. 
  • Acute and Chronic present medical conditions. 
  • Intake of greater than 15 mg of prednisone or equivalent per day. 
  • Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective birth control methods as per the research protocol. 
  • Have required management of acute or chronic infections. 
  • Have pre-existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits. 
  • Clinically significant lab abnormalities.
  • Any health condition that may be worsened by immunosuppression.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Jason Sluzevich, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20461643

Mayo Clinic Footer